MedImmune, Genentech Strike Deal In Synagis Case

Law360, New York (May 23, 2008, 12:00 AM EDT) -- Rival biotechnology companies MedImmune Inc. and Genentech Inc. have reached a deal in the patent suit over MedImmune's blockbuster drug Synagis, signaling the end of a dispute that led to the U.S. Supreme Court's January 2007 decision that a patent licensee could challenge a patent's validity without breaching or terminating the licensing agreement.

A Genentech spokesperson on Friday confirmed that the two companies had reached a settlement and would be seeking dismissal of the litigation, which is in the U.S. District Court for the Central District...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.